Results 131 to 140 of about 5,288 (183)

Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial. [PDF]

Ann Rheum Dis, 2023
Takeuchi T, Tanaka S, Murata M, Tanaka Y.   +3 more
europepmc   +1 more source

Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants. [PDF]

Clin Transl Sci, 2021
Scheible H, Dyroff M, Seithel-Keuth A, Harrison-Moench E, Mammasse N, Port A, Bachmann A, Dong J, van Lier JJ, Tracewell W, Mitchell D.   +10 more
europepmc   +1 more source

Evaluation of Cardiotoxicity in Lymphoproliferative Patients Treated With Anthracycline and Bruton's Tyrosine Kinase Inhibitor-Based Regimens. [PDF]

Cureus
Bonsu A.
europepmc   +1 more source

Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells. [PDF]

Front Pharmacol, 2022
Elbezanti WO, Al-Odat OS, Chitren R, Singh JK, Srivastava SK, Gowda K, Amin S, Robertson GP, Nemmara VV, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK.   +11 more
europepmc   +1 more source

Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton's Tyrosine Kinase Inhibitor: A Case Report. [PDF]

Cureus
Al-Shaker AN, Agarwal A, Saeed MT, Marney Z.   +3 more
europepmc   +1 more source

Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]

Cureus
Naseem A, Pednekar A, Patil S, Barkate H.   +3 more
europepmc   +1 more source

Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers. [PDF]

Front Oncol
Kluitmans DJF, Melis JJTM, van den Bossche E, Ytsma J, de Roos JADM, van Linden OPJ, Grobben Y, Kooijman JJ, Zaman GJR.   +8 more
europepmc   +1 more source

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]

J Comp Eff Res
Kittai AS, Patel DA, Shafrin J, Zawadzki N, Shetty VS, Barqawi YK, Rhodes JM.   +6 more
europepmc   +1 more source

Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease. [PDF]

Int J Mol Sci, 2021
Ziouti F, Rummler M, Steyn B, Thiele T, Seliger A, Duda GN, Bogen B, Willie BM, Jundt F.   +8 more
europepmc   +1 more source

RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cells. [PDF]

J Transl Int Med
Dong XD, Lu Q, Li YD, Cai CY, Teng QX, Lei ZN, Wei ZH, Yin F, Zeng L, Chen ZS.   +9 more
europepmc   +1 more source